Introduction
Burkitt's lymphomas (BLs) are characterized by chromosomal translocations [t(8;14) , t(8;2) or t(8;22)] that bring c-MYC into proximity with the immunoglobulin heavy or light chain loci (Dalla-Favera et al., 1982; Taub et al., 1982; Hamlyn and Rabbitts, 1983) . These translocations appear to lead to a dysregulation of c-MYC expression (for review see Johnston and Carroll, 1992) . In addition, it was early noted that the translocated c-MYC allele in several Burkitt's lymphoma lines had incorporated multiple mutations with these mutations being largely focused within the ®rst (non-translated) exon and ®rst intron of c-MYC although mutations also extended into exon 2 (Rabbitts et al., 1983b (Rabbitts et al., , 1984 Taub et al., 1984) . Two, nonmutually exclusive models have been forward to account for these mutations. Either the intrinsic mutation frequency of the translocated c-MYC is no higher than that of other expressed genes in the cell: rare c-MYC mutations could simply have been selected by virtue of a conferred growth advantage. Alternatively, translocation of c-MYC into the immunoglobulin loci could have transformed c-MYC into becoming a substrate for the antibody hypermutation mechanism and this is postulated to have been active at some stage following the creation of the translocation (Rabbitts et al., 1984; Taub et al., 1984; Cesarman et al., 1987) .
The hypermutation of immunoglobulin V genes is a process that is largely restricted to germinal centre B cells and plays a central role in the anity maturation of antibodies (reviewed in Parham, 1998) . Although the molecular mechanism of the hypermutation remains unidenti®ed, its target requirements have been extensively studied. Thus, the mutations (which are largely single nucleotide substitutions) are introduced into roughly 2 Kb regions located downstream of the transcription start sites of the productively rearranged immunoglobulin heavy and light chain genes (Lebecque and Gearhart, 1990) . The V gene, whilst the physiological target of the mutation, is not needed for mutation recruitment: other sequences can be mutated in its place (Yelamos et al., 1995) . Mutation recruitment depends upon the immunoglobulin transcription regulatory elements (Betz et al., 1994) with the location of the mutation domain being de®ned by the position of the transcription start site (Peters and Storb, 1996; Rada et al., 1997; Tumas-Brundage and Manser, 1997) . Whilst the immunoglobulin loci are certainly the preferred targets of the hypermutation, the process is not wholly exclusive to them: BCL-6 (but not several other genes analysed) has been found to be a natural target for the hypermutation process ± albeit at a much reduced mutation rate (Migliazza et al., 1995; Pasqualucci et al., 1998; Shen et al., 1998) .
In a search for an in vitro model in which to study immunoglobulin gene hypermutation, we recently identi®ed that the Ramos Burkitt's lymphoma cell line constitutively mutates its rearranged immunoglobulin V genes at high rate during in vitro culture (Sale and Neuberger, 1998) . This mutation shows the classic hallmarks of physiological immunoglobulin gene hypermutation. Since Ramos harbours a t(8;14) translocation in which c-MYC has been brought into the IgH locus (Figure 1a ), this cell line provides us with the means to ascertain whether the translocation itself does indeed convert c-MYC into becoming a substrate of the antibody hypermutation mechanism. location breakpoint lies upstream of the c-MYC promoter, the two c-MYC alleles can be distinguished within the transcribed region since the translocated allele has an A5234T mutation in exon 1 (Wiman et al., 1984) . This mutation allowed us to ask whether both c-MYC alleles are transcribed in Ramos. They are not. Of 19 cloned c-MYC cDNA RT ± PCR products, all derived from the translocated allele (Figure 1b) .
The translocated c-MYC has accumulated mutations
Comparison of the 19 c-MYC RT ± PCR products also revealed sequence heterogeneity. In addition to the A5234T mutation common to all the sequences, ®ve of the PCR products carried further mutations ( Figure  1b ). This frequency of mutation (16.8 bp 71 10
74
) is far in excess of the background error rate of the RT ± PCR technique itself (50.4 bp 71 10
in Cm (Sale and Neuberger, 1998) ) and presumably re¯ects the fact that Ramos has diversi®ed its translocated c-MYC during culture.
To de®nitively exclude any contribution by possible reverse transcriptase-induced artefacts, we sequenced c-MYC products that had been ampli®ed from genomic DNA. The ampli®ed regions extended from upstream of the promoter (using dierent primers to amplify the wild type and translocated alleles separately) to the intron downstream of exon 1 (Figure 1c) . With regard to the translocated allele, about one third of the 79 ampli®ed sequences were mutated with between 1 and 4 mutations per sequence. In total, 25 distinct mutations were identi®ed on this allele, three of which were insertions of deletions (Table 1) . These results are most unlikely to re¯ect PCR artefact. Not only is the frequency of mutation considerably in excess of that obtained in the PCR control (Table 1 ) but also two of the mutations were detected in independent PCR ampli®cations (G4894C and C5034G). Moreover, three of the mutations identi®ed in the genomic PCR had also been identi®ed amongst the RT ± PCR products (C4274T, G4894C and C5034G).
In contrast to these observations with regard to the translocated c-MYC, only four of the 70 sequences (Bernard et al., 1983; Wiman et al., 1984) . (b) Analysis of expressed c-MYC in Ramos by RT ± PCR. The sequence diversity amongst 19 c-MYC RT ± PCR products is illustrated by Pie charts. The digit in the centre of the Pie indicates the number of sequences that were obtained from each of the c-MYC alleles and the digits¯anking each segment of the Pie indicate the number of mutations that were found in 250 base pairs around the exon 1/ exon 2 border (139 bp in exon 1, 111 in exon 2). The two c-MYC alleles could be discriminated by virtue of the A5234T mutation on the translocated allele (Wiman et al., 1984) . (c) Analysis of sequence diversity of the two Ramos c-MYC alleles by genomic PCR. Separate PCR reactions were used to amplify the two c-MYC alleles; the locations of the primers used (arrows) and of the regions sequenced (thin lines) are shown in the left-hand side of this panel. To the right, Pie charts depict the distribution of mutated sequences. (d) Analysis of sequence diversity in BCL-6 and the ribosomal S14 gene Oncogene c-MYC hypermutation in Burkitt's lymphoma M Bemark and MS Neuberger deriving from exon 1 of the untranslocated c-MYC were mutated and, even then, there was a maximum of one mutation per sequence. This degree of mutation does not rise signi®cantly above the background attributable to PCR error alone ( Figure 1 ). Thus, mutation of the Ramos c-MYC appears to be peculiar to the translocated allele. Mutation is also peculiar to the transcribed portion of the translocated c-MYC since mutations were not detected in the region immediately 5' of the c-MYC promoter on either allele (Table 1 and Figure 1c ).
We were interested in comparing the mutation accumulation in c-MYC with that in two other genes: BCL-6, which has earlier been shown to undergo somatic hypermutation at a rate of about 1% that of the immunoglobulin genes, and the ribosomal S14 gene which has been found to be expressed but not mutated in primary B cells (Pasqualucci et al., 1998; Shen et al., 1998) . The frequency of mutations detected at both these loci in Ramos is not signi®cantly above the PCR error rate.
The translocated c-MYC mutates constitutively in culture
These results revealed that Ramos had, at some stage, accumulated mutations in its translocated c-MYC. Considering the extended period over which our Ramos culture had been serially subcultured, we suspected that many of the mutations that we had detected had probably been generated relatively recently. To con®rm that the translocated c-MYC was constitutively accumulating mutations during routine culture, we analysed c-MYC diversity in a Ramos subclone that had been generated by limiting dilution and was then expanded and serially subcultured in RPMI/10%FBS for a period of 6 months.
As in the parental population, genomic PCR analysis of the two c-MYC alleles in the Ramos subclone revealed multiple mutations on the translocated allele but only one on the germline allele ( Figure 2a and Table 2 ). Some of these sequences could be arranged into a dynasty with the mutations presumably therefore having accumulated stepwise (Figure 2b) .
We also compared the diversity that had accumulated in the translocated c-MYC of the Ramos subclone to that accumulated in the productively rearranged V H segment ( Table 2 ). The rate of V H mutation was about twofold higher than for the translocated c-MYC, a result which is in broad agreement with the relative prevalence of c-MYC and V H mutations in our original oligoclonal Ramos population (V H threefold higher than translocated c-MYC; Figure 1c ).
c-MYC mutations are characteristic of somatic hypermutation
The mutations detected in the translocated c-MYC are evenly spread over exon 1 (Figure 3a) . Although we have not de®ned the 3'-border of the mutation domain, the 5'-border ± like that in immunoglobulin V genes ± appears to be downstream of the transcription start. As with immunoglobulin hypermutation, the c-MYC mutations observed are largely nucleotide substitutions (33 of the 38 independent events) with a preference for transitions over transversions (52% rather than the randomly expected 33%). The ®ve deletions or Figure 2 The translocated c-MYC of Ramos diversi®es constitutively in culture. Sequence diversity was analysed by genomic PCR from a Ramos culture that had been generated by limiting dilution cloning (Sale and Neuberger, 1998) duplications/insertion events detected were either found adjacent to positions that had been identi®ed as point mutated in other sequences or in a stretch of seven T's located at the end of exon 1.
Most striking, however, is the preferential targeting of the mutations to C or G residues (32/33 of the nucleotide substitutions) with 52% of the mutations occurring at AGC triplets. [Given the sequence of the target, random mutational targeting would have yielded 18% of the mutations at AGC]. Such highly focused mutational targeting is also a feature of immunoglobulin hypermutation in the Ramos cell line as discussed below. In contrast, the rare mutations that we observed in the ampli®ed BCL-6 and S14 genes (where the mutation frequency did not rise signi®cantly above the PCR error rate) showed no preference for AGC hotspots.
Discussion
The proposition that translocation of c-MYC into the IgH locus causes it to become a target of the antibody hypermutation mechanism has previously been put forward based on the detection of c-MYC mutations and sequence heterogeneity in BL cell-lines, tumour biopsies and primary tissue samples (Rabbitts et al., 1983b (Rabbitts et al., , 1984 Taub et al., 1984; Johnston et al., 1991; MuÈ ller et al., 1995) . Our demonstration that the translocated c-MYC (but not the germline c-MYC allele or other control genes) undergoes constitutive hypermutation in the Ramos cell line at a rate comparable to that of IgV genes gives strong support to such proposals. The pattern of c-MYC mutations show the characteristic features of antibody hypermutation. The mutations are largely introduced into a domain downstream of the transcription start-site: rare mutations upstream of the canonical transcription start could re¯ect occasional transcriptional initiation at upstream c-MYC promoters (Bentley and Groudine, 1986) or within IgH sequences. Most mutations are single nucleotide substitutions with a preference for transitions, although, as in immunoglobulin hypermutation (particularly in humans Goossens et al., 1998; Wilson et al., 1998) a minor proportion are deletions and nucleotide insertions/duplications.
The distribution of c-MYC mutations that we have detected in the cultured Ramos cell line is very similar to that described in others BLs (KOBK1, Raji, PA682, Daudi, BL2, BL22 and eBL3; Figure 3) . Thus, 43% of Figure 3 Mutations detected in the ®rst exon of the translocated c-MYC. (a) The sequence of c-MYC is presented with position 1 being the start-site of transcripts initiated at the P1 promoter (the major promoter used by the Ramos translocated c-MYC (Bernard et al., 1983) ). The transcription start site from the P2 promoter is also indicated. Above the line (in upper case letters) are indicated the independent mutations identi®ed downstream of position 98 in the translocated Ramos c-MYC in this work; all except two (G4334A, G5254A) derive from the genomic PCR analysis. Below the line (in lower case letters) are indicated c-MYC point mutations that have been described in other BLs (data taken from Rabbitts et al., 1983b Rabbitts et al., , 1984 Taub et al., 1984; Showe et al., 1987; Zajec-Kaye et al., 1988; Morse et al., 1989; Tachibana et al., 1993) . Note that in some of the cell lines only parts of exon 1 was sequenced. Underlining highlights AGC triplets on either strand, and the major transcriptional pausing/termination site Ta/TI is boxed (Chung et al., 1987) . (b) Deletions and insertions in the c-MYC ®rst intron identi®ed in this work. Note that in the two last cases, the exact location for the insertion/duplication events within the oligo-dT stretch cannot be determined. The 2 bp insertion event was identi®ed in the RT ± PCR analysis Table 3 Nature of mutations in translocated Ramos c-MYC
Oncogene c-MYC hypermutation in Burkitt's lymphoma M Bemark and MS Neuberger the positions in c-MYC that were mutated in Ramos are also found to have been targeted in at least one of the other BL lines (against a random expectation of 15%). A non-random distribution of mutations could in principle be attributed to a skewing eect of selection or to intrinsic non-randomness of the mutational process. In this case, we believe that the explanation is largely provided by the intrinsic bias of the mutational process. The intrinsic features of antibody hypermutation have been extensively studied: mutations are introduced non-randomly with a marked preference for hotspots, the sequences of many of these hotpots conforming to an AGC consensus (Betz et al., 1993) . It is notable therefore that 52% of Ramos c-MYC mutations and 42% of the mutations in the other BLs are at AGC against a randomly expected 18%.
Even more striking is the G/C biased nature of the mutational targeting. Thus, 32/33 nucleotide substitutions in Ramos c-MYC and 69/89 nucleotide substitutions in the c-MYCs of the other BLs are at G/C; this is against a random expectation of 62% in the target sequence. Such a marked preference for mutations at G/C has previously been noted as a feature of antibody hypermutation in Ramos and other BLs (Sale and Neuberger, 1998) but is not, however, a feature of in vivo hypermutation in man and mouse (Betz et al., 1993; . This implies, as previously discussed (Sale and Neuberger, 1998) , that the antibody hypermutation process occurring in BLs, like that in Msh2-de®cient mice (Rada et al., 1998; Frey et al., 1998) , exhibits some distinction from that taking place in germinal centre B cells of higher organisms. The G/ C bias of the mutations in the BL lines therefore suggests that few of their c-MYC mutations can have been incorporated during the early, pre-transformation life of the cell.
The mutations that we have detected in Ramos are peculiar to the rearranged immunoglobulin V genes and the translocated c-MYC. Mutability was not detected at the germline c-MYC locus or in the ribosomal S14 or BCL-6 genes. Our failure to detect mutability at BCL-6 may at ®rst sight surprise in view of the evidence indicating that BCL-6 acts as a substrate for the antibody hypermutation process in vivo. However, the in vivo mutability of BCL-6 has been estimated as being one to two orders of magnitude below that of the immunoglobulin loci; it may well therefore have fallen below our level of detection (Pasqualucci et al., 1998; Shen et al., 1998) .
The results also give some insight into the cis-acting sequences needed to confer mutability. Thus, from this work it appears that IgH sequences downstream of Sm suce for this purpose and that the IgH intronic enhancer is not required. Interestingly, it was a similar observation that translocated c-MYC transcription is independent of the intronic enhancer that led to the search for IgH 3'-enhancers (Neuberger and Calabi, 1983; Rabbitts et al., 1983a; Pettersson et al., 1990) . Not only might these downstream enhancers play an important role in V gene mutation (as discussed by Tumas-Brundage et al. (1996) ) and in c-MYC hypermutation; they might also make the intronic enhancer dispensable for mutability.
A connection between mutability and transcription has been noted in several studies (Betz et al., 1994; Peters and Storb, 1996; Goyenechea et al., 1997; Fukita et al., 1998) and Peters and Storb (1996) have proposed that transcriptional pausing may play a role in hypermutation. Transcriptional pause sites in c-MYC are amongst the best characterized of those in mammalian RNA polymerase II transcription units (Bentley and Groudine, 1986; Chung et al., 1987; Kerppola and Kane, 1988; Strobl and Eick, 1992; Keene et al., 1999) . There is no obvious correlation between the single nucleotide mutations detected in the c-MYC exon 1 and the major polymerase II pausing/ termination site described in this exon. Thus, the data do not lend any strong support to a connection between transcriptional pausing and antibody hypermutation although (I) the pause sites in the translocated c-MYC could dier from those in the germline allele (Spencer et al., 1990) and (II) two of the three insertion/duplication events that we observed in the Ramos c-MYC are within the homopolymeric dT stretch that constitutes the major exon 1 pause site.
Finally, it is interesting to ask whether the hypermutability of the translocated c-MYC contributes to leukaemogenesis. Or does the chromosomal translocation simply lead to a deregulation of c-MYC transcription with the increased mutability being an inevitable consequence of the translocation event ± but one of little relevance to the biology of the tumour? With respect to the c-MYC mutations deleted in this work, it is unlikely that any of them confer a proliferative advantage or contribute to leukaemogenesis. The pattern of mutations detected conforms to the intrinsic speci®city of the hypermutation mechanism with no evidence of any skewing eect of selection. Furthermore, the only consensus dierence between the expressed c-MYC gene in our starting Ramos culture and its germline counterpart is an A5234T mutation in exon 1 ± a mutation that is not observed in the other BLs analysed. However, it remains fully possible that mutations in c-MYC that lie outside the region analysed in this work or that mutations in other protooncogenes that have been translocated into the immunoglobulin loci could well contribute to leukaemogenesis. One example is the c-MYC box 1 motif that is found at the NH 2 -terminus of the mature protein and is encoded in exon 2. This motif is often mutated and such mutations have recently been shown to decrease the ubiquitin/proteasome-mediated turnover of c-MYC protein (Bahram et al., 2000; Gregory and Han, 2000) .
Materials and methods

Cell culture
Ramos and the subclone Rc14 were cultured as described by Sale and Neuberger (1998) .
DNA preparation and analysis
Genomic DNA was prepared from between 4 ± 20610 6 cells using either QIAamp DNA blood mini kit (Qiagen), and cDNA was prepared according to standard procedures from total RNA isolated using Trizol reagent (Life Technologies). The PCRs were performed using pfuTurbo polymerase (Stratagene) as recommended by the manufacturer with between 1 ± 1/10 ml of DNA in a total reaction volume of 50 ml. The PCR program was 30 cycles (958C for 1 min, 558C for 30 s, and 728C for 2 min), except for the VH PCR which was performed exactly as described (Sale and Neuberger, 1998) . The primers used in the other PCRs were as follows: c-MYC cDNA 5' primer: CAGGGTACCGGCACTTTGCACTGGAACTT 3' primer: CAGGAGCTCTCTGGTTCACCATGTCTCCT C-MYC genomic 5' primer, translocated allele: CAGGGTACCCTGTTCAGCACAGCACATC 5' primer, wild type allele: CAGGGTACCTCCCTGGGACTCTTGATCAA 3' primer: CAGGAGCTCTTCGGTGCTTACCTGGTTT BCL-6 5' primer: CAGGGTACCAAAATCCACCGATGCCGATC 3' primer: CAGGAGCTCTCAATTCTCGGAATTTGAGC S14 5' primer: CGGGGTACCCGGGACAGACGTGGGCTCCCG 3' primer: CAGGAGCTCTAAGGGAGAGAGAAACTGAC The PCR products were puri®ed using Qiagen PCR puri®cation kit, digested with SacI/KpnI, repuri®ed with the PCR puri®cation kit and ®nally cloned into pBluescript (Stratagene) between the SacI and KpnI sites. Plasmids were prepared using QIAprep 8 Turbo kits (Qiagen), and were sequenced from the T3 and T7 promoters on an ABI 377 sequencer. The sequences were aligned and analysed using the GAP4 alignment program.
